Cardiac Rhythm Management Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

Cardiac Rhythm Management Devices Market Summary

The global cardiac rhythm management devices market is expected to increase from USD 16,100.21 million in 2024 to USD 24,079.86 million by 2032, reflecting strong and sustained growth.

The global cardiac rhythm management devices market is growing at a CAGR of 5.23% during the forecast period from 2025 to 2032.

The cardiac rhythm management devices market is primarily fueled by the increasing prevalence of cardiovascular diseases, heightened awareness and early diagnosis, a growing shift toward minimally invasive procedures, and the expanding geriatric population, among other factors.

The leading companies operating in the cardiac rhythm management devices market include Abbott, Medtronic, Boston Scientific Corporation, Koninklijke Philips N.V., Zoll Medical Corporation, Microport Scientific Corporation, LivaNova PLC, Biotronik, Inc., Nihon Kohden Corporation, Shree Pacetronix Ltd., OSCOR Inc., Lepu Medical Technology Co. Ltd., Stryker, BPL Medical Technologies, ICU Medical Systems, Inc., SCHILLER AG, Bexen Cardio, Progetti S.r.l., Vitatron, Kestra Medical Technologies, Inc., and others.

The North American cardiac rhythm management devices market is witnessing strong growth, driven by a high prevalence of cardiovascular diseases, rapid technological advancements, and a well-established healthcare infrastructure.

In the product type segment of the cardiac rhythm management devices market, the defibrillators category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of the Cardiac Rhythm Management Devices Market

Growing instances of cardiovascular diseases and their associated risk factors leading to a surge in cardiac rhythm management devices: The rising burden of cardiovascular diseases, including arrhythmias, heart failure, and sudden cardiac arrest, is a major driver of the cardiac rhythm management (CRM) devices market. Lifestyle-related risk factors such as obesity, hypertension, diabetes, stress, and sedentary habits are further increasing the incidence of heart rhythm disorders across populations. As these conditions often require timely intervention, there is a growing demand for devices such as pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) systems to restore and regulate normal heart function. This surge in disease prevalence continues to fuel market expansion globally.

Increasing awareness and timely diagnosis are significantly accelerating the growth of the cardiac rhythm management devices market: Improved awareness of cardiac health and the availability of advanced diagnostic tools are significantly contributing to the uptake of CRM devices. With initiatives from healthcare providers, governments, and NGOs promoting preventive care, more individuals are undergoing routine heart health screenings. Early detection of conditions such as atrial fibrillation or bradycardia allows for timely treatment, often through the implantation of pacemakers or defibrillators. Additionally, technological integration in diagnostic tools, such as wearable monitors and AI-enabled ECG devices, is making diagnosis more accessible and accurate, ultimately driving device adoption.

Increasing shift toward minimally invasive procedures: Patient preference for less invasive treatment options is shaping the CRM devices market. Minimally invasive implantation techniques for pacemakers and defibrillators are gaining traction due to their benefits of shorter hospital stays, reduced risk of infection, quicker recovery times, and minimal scarring. The development of leadless pacemakers and subcutaneous implantable cardioverter defibrillators (S-ICDs) is revolutionizing treatment by eliminating the need for traditional surgical leads, thus reducing procedural complications. This shift toward minimally invasive approaches not only improves patient outcomes but also encourages wider acceptance of CRM technologies among both patients and healthcare providers.

Cardiac Rhythm Management Devices Market Report Segmentation

This Cardiac Rhythm Management Devices market report offers a comprehensive overview of the global Cardiac Rhythm Management Devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy (CRT) Devices), End-Users (Hospitals and clinics, Ambulatory Surgical Centers, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing cardiac rhythm management devices market.

Cardiac Rhythm Management (CRM) Devices are medical devices designed to monitor and regulate abnormal heart rhythms (arrhythmias). These include pacemakers, which correct slow heartbeats; implantable cardioverter defibrillators (ICDs), which detect and stop dangerous fast rhythms; and cardiac resynchronization therapy (CRT) devices, which improve the heart’s pumping efficiency in heart failure patients. Together, they help maintain proper cardiac rhythm, reduce the risk of sudden cardiac arrest, and improve overall heart function.

The global cardiac rhythm management (CRM) devices market is growing primarily due to the rising global prevalence of cardiovascular diseases (CVDs), such as arrhythmias, atrial fibrillation, and heart failure, which is further exacerbated by an aging global population that is more susceptible to these conditions. Crucially, the market is propelled by significant technological advancements, including the development of leadless pacemakers, MRI-compatible devices, and the integration of remote monitoring capabilities and Artificial Intelligence (AI) for real-time patient management and predictive analytics. This innovation enhances device efficacy, minimizes invasiveness, and improves patient outcomes, while supportive reimbursement policies and expanding healthcare infrastructure worldwide also contribute to the increasing adoption of these essential life-saving and life-enhancing medical technologies.

Collectively, these drivers are not only expanding the market but also accelerating innovation, paving the way for sustained growth in the years ahead.

Get More Insights into the Report @Cardiac Rhythm Management Devices Market

What are the latest Cardiac Rhythm Management Devices Market Dynamics and Trends?

The global cardiac rhythm management devices market is experiencing robust growth, fuelled by the rising prevalence of cardiovascular diseases and the growing need for advanced monitoring and interventional solutions.

According to DelveInsight’s analysis (2024), an estimated 621.5 million people worldwide, approximately 1 in 13 individuals, live with heart and circulatory diseases, underscoring the vast scale of the challenge. Of these, around 100 million cases are in Europe and 340 million in Asia and Australia, highlighting the extensive geographic impact of cardiovascular disorders.

Among these conditions, arrhythmias, particularly atrial fibrillation (AF), are emerging as major contributors to sudden cardiac events. The analysis further indicates that nearly 60 million people globally are affected by AF, a condition that significantly increases the risk of stroke, heart failure, and sudden cardiac arrest. In Australia alone, more than 500,000 people were diagnosed with AF during the same period. Additionally, stroke survivors globally account for approximately 56 million women and 45 million men, while at least 13 million people live with congenital heart disease, with millions more potentially undiagnosed. These conditions, often linked to irregular heart rhythms, sharply elevate the risk of life-threatening cardiac emergencies, where defibrillators and other rhythm management devices play a critical and lifesaving role.

Looking ahead, it is projected that by 2030, over 12.5 million people will be affected by atrial fibrillation worldwide, a condition that frequently necessitates interventional support to prevent heart failure and related complications. Coronary (ischemic) heart disease, the most commonly diagnosed cardiovascular condition, affects approximately 200 million people globally, including 110 million men and 80 million women, further emphasizing the urgent need for timely monitoring and intervention.

Cardiac Rhythm Management Devices, including pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) systems, play a pivotal role in tracking heart function, detecting abnormalities, and enabling early interventions. These devices help manage arrhythmias and other cardiac disorders, reduce the risk of sudden cardiac events, and improve overall patient outcomes.

Thus, the escalating prevalence of cardiovascular diseases, rising incidence of arrhythmias, continuous technological innovations in monitoring and interventional devices, growth of the geriatric population, and increasing adoption of remote patient monitoring are collectively driving the expansion of the Cardiac Rhythm Management Devices market. The combination of a large and growing patient pool, advancements in device technology, and a shift toward proactive, data-driven cardiac care is expected to sustain market growth throughout the forecast period.

Although the cardiac rhythm management devices market is expanding steadily, it faces several challenges that could restrain its growth. One significant concern is the complications associated with various devices, as patients may experience issues such as lead dislodgement, infection at the implantation site, device malfunction, or inappropriate shocks from defibrillators, which can impact patient safety and treatment outcomes. These complications necessitate careful monitoring and follow-up, which can sometimes limit adoption or lead to increased healthcare costs. In addition, the stringent regulatory approval process for cardiac rhythm management devices, involving rigorous clinical trials and compliance with FDA, CE, and other international standards, can delay product launches and increase development costs.

Together, these factors, device-related complications, and complex regulatory requirements pose notable challenges, influencing market dynamics and requiring manufacturers to continuously focus on innovation, safety, and compliance to maintain growth.

Cardiac Rhythm Management Devices Market Segment Analysis

Cardiac Rhythm Management Devices Market by Product Type (Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy (CRT) Devices), End-Users (Hospitals and clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Cardiac Rhythm Management Devices Market Regional Analysis

North America Cardiac Rhythm Management Devices Market Trends

North America is projected to hold the largest share of 45% in the global Cardiac Rhythm Management Devices market in 2024. The North American cardiac rhythm management devices market is witnessing strong growth, driven by a high prevalence of cardiovascular diseases, rapid technological advancements, and well-established healthcare infrastructure.

According to DelveInsight’s 2024 analysis, approximately 4.0% of U.S. adults were diagnosed with coronary heart disease, while an estimated 12.2 million people were living with atrial fibrillation by 2023. The significant burden of heart rhythm disorders, particularly among the aging population, is fueling demand for advanced devices such as pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) systems.

Continuous innovation and regulatory approvals are further reinforcing market momentum in the U.S. In October 2023, the U.S. Food and Drug Administration (FDA) approved Medtronic’s Aurora EV-ICD™ MRI SureScan™ and the Epsila EV™ MRI SureScan™ defibrillation lead, representing a breakthrough in extravascular ICD technology. These next-generation devices are designed to manage dangerously rapid heart rhythms associated with sudden cardiac arrest while minimizing complications linked to traditional transvenous leads. This approval highlights a broader industry trend toward minimally invasive, patient-centric technologies that enhance safety, comfort, and clinical outcomes.

Technological advancements are a key driver of the market, with innovations such as leadless pacemakers, subcutaneous defibrillators, and AI-enabled remote monitoring systems becoming increasingly adopted. These technologies allow for continuous cardiac monitoring, early detection of arrhythmias, and personalized therapy adjustments, improving patient management and reducing hospital readmissions. Additionally, growing awareness among patients and physicians, along with early diagnosis initiatives and preventive care programs, is boosting device adoption across the region.

The competitive landscape in North America is dominated by global leaders like Medtronic, Abbott, and Boston Scientific, who invest heavily in research and development, clinical trials, and strategic partnerships to maintain technological leadership. Coupled with favorable reimbursement policies and a strong healthcare delivery system, these factors are driving sustained growth in the North American cardiac rhythm management devices market. The combination of high disease prevalence, continuous innovation, patient-centric technology, and robust healthcare infrastructure positions North America as one of the largest and most advanced markets for cardiac rhythm management devices.

Europe Cardiac Rhythm Management Devices Market Trends

The Cardiac Rhythm Management (CRM) devices market in Europe is experiencing steady growth, underpinned by the region’s rapidly aging population and the high prevalence of cardiovascular diseases (CVDs), which remain the leading cause of morbidity and mortality across the continent. This demand is reinforced by the rising incidence of arrhythmias, heart failure, and ischemic heart disease, all of which significantly increase the need for pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) systems.

A defining trend in the European market is the accelerating adoption of next-generation CRM technologies, particularly leadless pacemakers and subcutaneous ICDs (S-ICDs), which are favored for their minimally invasive implantation procedures, reduced complication risks, and improved patient comfort. The market is also benefiting from the widespread integration of remote patient monitoring (RPM) and telemedicine platforms, which allow continuous real-time cardiac data transmission from home to healthcare providers. This shift supports value-based care models by improving patient outcomes, reducing unplanned hospitalizations, and optimizing long-term management of chronic cardiac conditions.

Technological advancements continue to expand the clinical utility of CRM devices. Features such as MRI-compatibility, longer battery life, and enhanced device miniaturization are now standard, while the early integration of Artificial Intelligence (AI) is enabling predictive analytics to detect arrhythmia risks, personalize therapy, and improve device programming. These innovations are reshaping care delivery by aligning with Europe’s broader focus on preventive and precision medicine.

Geographically, Germany, the UK, and France remain the strongest contributors to market revenues, supported by highly developed healthcare systems, high implant volumes, favorable reimbursement frameworks, and robust cardiology research networks. Meanwhile, Southern and Eastern Europe are witnessing rising adoption due to improving healthcare access and growing investments in cardiac care infrastructure.

In addition to implantable devices, the European market is being bolstered by increased public health initiatives promoting the deployment of Automated External Defibrillators (AEDs) in airports, schools, workplaces, and even private residences. These efforts reflect a region-wide emphasis on early intervention in sudden cardiac arrest, complementing the clinical use of implantable devices.

Overall, Europe’s CRM devices market is set to maintain strong momentum, driven by a large and growing patient pool, rapid technological innovation, and healthcare systems that increasingly prioritize remote monitoring, minimally invasive solutions, and data-driven cardiac care.

Asia-Pacific Cardiac Rhythm Management Devices Market Trends

The Asia-Pacific cardiac rhythm management (CRM) devices market is witnessing significant growth, driven by the rising prevalence of cardiovascular diseases, increasing awareness of heart health, and expanding healthcare infrastructure across the region. Countries such as China, Japan, India, and South Korea are leading adoption due to the growing geriatric population and higher incidence of arrhythmias and heart failure. Technological advancements, including leadless pacemakers, subcutaneous defibrillators, and AI-enabled remote monitoring systems, are gaining traction as hospitals and clinics seek to improve patient outcomes while reducing procedural risks.

Furthermore, government initiatives to improve cardiac care, coupled with rising healthcare expenditure and insurance coverage, are enhancing accessibility to advanced devices. The region is also experiencing a shift toward minimally invasive procedures, driven by patient preference for faster recovery and reduced complications. Emerging local manufacturers are entering the market alongside established global players, intensifying competition and encouraging innovation tailored to regional needs.

Therefore, the combination of demographic trends, technological adoption, and healthcare development is positioning Asia-Pacific as one of the fastest-growing markets for CRM devices in the coming years.

Who are the major players in the cardiac rhythm management devices market?

The following are the leading companies in the cardiac rhythm management devices market. These companies collectively hold the largest market share and dictate industry trends.

Abbott

Medtronic

Boston Scientific Corporation

Koninklijke Philips N.V.

Zoll Medical Corporation

Microport Scientific Corporation

LivaNova PLC

Biotronik, Inc.

Nihon Kohden Corporation

Shree Pacetronix Ltd.

OSCOR Inc.

Lepu Medical Technology Co., Ltd.

Stryker

BPL Medical Technologies

ICU Medical Systems, Inc.

SCHILLER AG

Bexen Cardio

Progetti S.r.l.

Vitatron

Kestra Medical Technologies, Inc.

How is the competitive landscape shaping the cardiac rhythm management devices market?

The competitive landscape of the Cardiac Rhythm Management (CRM) Devices market is highly concentrated, with a few global leaders dominating the space and setting industry benchmarks. Companies such as Medtronic, Abbott, Boston Scientific, and Biotronik hold a commanding position owing to their extensive product portfolios, global distribution networks, and robust clinical trial support. Their strong market presence is reinforced by continuous investments in innovation, leading to the development of advanced solutions such as leadless pacemakers, subcutaneous implantable defibrillators, and AI-driven monitoring technologies that enhance accuracy, safety, and patient outcomes. Smaller players and emerging companies often compete in niche segments by focusing on product specialization or regional markets, but face challenges in matching the scale, regulatory expertise, and financial strength of these established giants.

Strategic partnerships, mergers, and acquisitions are a defining trend, enabling leading firms to expand their technological capabilities, address product gaps, and strengthen their foothold in emerging regions. North America continues to dominate due to a high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and favorable reimbursement frameworks, while Asia-Pacific is emerging as a high-growth region, driven by rising healthcare expenditure, larger patient pools, and improving access to advanced therapies.

Despite these opportunities, companies face significant hurdles, including stringent regulatory approvals, high R&D and manufacturing costs, and growing pressure from healthcare providers and payers to deliver cost-effective solutions. As a result, competition is increasingly focused not only on technological advancement but also on delivering value-based care, ensuring reliability, and expanding access in cost-sensitive markets.

This interplay of innovation, consolidation, and regional growth strategies is shaping the long-term trajectory of the CRM devices market.

Recent Developmental Activities in the Cardiac Rhythm Management Devices Market

In May 2025, Element Science gained FDA approval for the Jewel Patch Wearable Cardioverter Defibrillator (WCD), a lightweight patch with embedded AI algorithms to minimize false alarms and inappropriate shocks, offering new options for high-risk patients who are not yet candidates for permanent implants.

In March 2025, Medtronic Japan Co., Ltd. announced the successive launch in Japan of the Aurora EV-ICD™ MRI device and the Epsila EV™ MRI Lead (collectively referred to as the Aurora EV-ICD system), designed for the treatment of ventricular arrhythmias.

In March 2025, Medtronic secures FDA approval for the OmniaSecure™ lead, the smallest-diameter, lumenless defibrillation lead, and shares results from its investigational clinical study.

Cardiac Rhythm Management Devices Market Segmentation

Cardiac Rhythm Management Devices by Product Type Exposure

• Pacemakers
• Defibrillators
• Cardiac Resynchronization Therapy (CRT) Devices

Cardiac Rhythm Management Devices End-Users Exposure

• Hospitals and clinics
• Ambulatory Surgical Centers
• Others

Cardiac Rhythm Management Devices Geography Exposure

• North America Cardiac Rhythm Management Devices Market

United States Cardiac Rhythm Management Devices Market

Canada Cardiac Rhythm Management Devices Market

Mexico Cardiac Rhythm Management Devices Market

• Europe Cardiac Rhythm Management Devices Market

United Kingdom Cardiac Rhythm Management Devices Market

Germany Cardiac Rhythm Management Devices Market

France Cardiac Rhythm Management Devices Market

Italy Cardiac Rhythm Management Devices Market

Spain Cardiac Rhythm Management Devices Market

Rest of Europe Cardiac Rhythm Management Devices Market

• Asia-Pacific Cardiac Rhythm Management Devices Market

China Cardiac Rhythm Management Devices Market

Japan Cardiac Rhythm Management Devices Market

India Cardiac Rhythm Management Devices Market

Australia Cardiac Rhythm Management Devices Market

South Korea Cardiac Rhythm Management Devices Market

Rest of Asia-Pacific Cardiac Rhythm Management Devices

• Rest of the World Cardiac Rhythm Management Devices Market

South America Cardiac Rhythm Management Devices Market

Middle East Cardiac Rhythm Management Devices Market

Africa Cardiac Rhythm Management Devices Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-Powered Innovations and Applications are revolutionizing the cardiac rhythm management (CRM) devices market, offering advanced solutions that go beyond traditional monitoring and therapy. The integration of artificial intelligence into pacemakers, defibrillators, and cardiac resynchronization therapy (CRT) systems is enabling real-time data analysis and predictive insights, significantly improving patient safety and treatment outcomes. Machine learning algorithms can detect subtle changes in heart rhythm patterns that may be missed by conventional monitoring, allowing for earlier diagnosis of arrhythmias and timely medical intervention. This not only reduces the risk of sudden cardiac arrest but also helps physicians personalize therapies according to each patient’s clinical profile.

Furthermore, AI-powered platforms are enhancing remote patient monitoring by analyzing continuous streams of cardiac data transmitted from implanted devices. These systems can alert healthcare providers to potential complications before they become critical, thereby reducing hospitalizations and improving long-term disease management. For patients, this translates into greater confidence, fewer clinic visits, and a better quality of life. In addition, AI-driven innovations are being applied to optimize device programming, minimize energy consumption, and extend battery life, which lowers the need for frequent replacement surgeries.

Beyond clinical care, artificial intelligence is playing a pivotal role in research and development by accelerating device design, supporting clinical trial analysis, and identifying new therapeutic approaches through big data insights. As healthcare systems increasingly move toward preventive and value-based care models, AI-powered CRM applications are aligning perfectly with these priorities by providing accurate, cost-effective, and patient-centric solutions.

Collectively, these advancements underscore the potential of AI not just as a supportive tool but as a transformative force in shaping the future of cardiac rhythm management.

U.S. Tariff Impact Analysis on Cardiac Rhythm Management Devices Market:

The U.S. tariff policies have a notable influence on the cardiac rhythm management (CRM) devices market, particularly given the globalized nature of medical device manufacturing and supply chains. Many components used in pacemakers, defibrillators, and cardiac resynchronization therapy (CRT) devices, such as semiconductors, batteries, and specialized metals, are sourced internationally. The imposition of tariffs on imported raw materials or finished devices can drive up production costs for manufacturers, which may, in turn, lead to higher pricing for healthcare providers and patients. This creates pressure on companies to optimize operations, explore local sourcing, or shift manufacturing to tariff-friendly regions.

At the same time, tariffs may encourage domestic manufacturing initiatives by incentivizing companies to establish or expand production facilities within the U.S. to mitigate additional costs. While this could strengthen the U.S. medical device industry in the long term, the immediate impact often includes supply chain disruptions, longer lead times, and margin pressures for global players operating in the CRM space. For patients and healthcare systems, higher tariffs may translate into increased device costs, which could challenge affordability and accessibility, especially in cases where reimbursement policies do not fully absorb the additional expenses.

Thus, U.S. tariff policies act as both a challenge and an opportunity, creating short-term hurdles for manufacturers while potentially driving greater domestic innovation and supply chain resilience in the cardiac rhythm management devices market.

How This Analysis Helps Clients

Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.

Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.

Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.

Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Cardiac Rhythm Management Devices market report study

Market size analysis for the current cardiac rhythm management devices market size (2024), and market forecast for 8 years (2025 to 2032)

Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.

Key companies dominating the cardiac rhythm management devices market.

Various opportunities available for the other competitors in the cardiac rhythm management devices market space.

What are the top-performing segments in 2024How these segments will perform in 2032?

Which are the top-performing regions and countries in the current cardiac rhythm management devices market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for the cardiac rhythm management devices market growth in the future?

Frequently Asked Questions for the Cardiac Rhythm Management Devices Market

1. What is the growth rate of the cardiac rhythm management devices market?

The cardiac rhythm management devices market is estimated to grow at a CAGR of 5.23% during the forecast period from 2025 to 2032.

2. What is the market for cardiac rhythm management devices?

The cardiac rhythm management devices market was valued at USD 16,100.21 million in 2024, and is expected to reach USD 24,079.86 million by 2032.

3. Which region has the highest share in the Cardiac Rhythm Management Devices market?

The North American cardiac rhythm management devices market is witnessing strong growth, driven by a high prevalence of cardiovascular diseases, rapid technological advancements, and a well-established healthcare infrastructure.

4. What are the drivers for the cardiac rhythm management devices market?

The cardiac rhythm management devices market is primarily fuelled by the increasing prevalence of cardiovascular diseases, heightened awareness and early diagnosis, a growing shift toward minimally invasive procedures, and the expanding geriatric population, among other factors.

5. Who are the key players operating in the cardiac rhythm management devices market?

Some of the key market players operating in the cardiac rhythm management devices market include Abbott, Medtronic, Boston Scientific Corporation, Koninklijke Philips N.V., Zoll Medical Corporation, Microport Scientific Corporation, LivaNova PLC, Biotronik, Inc., Nihon Kohden Corporation, Shree Pacetronix Ltd., OSCOR Inc., Lepu Medical Technology Co., Ltd., Stryker, BPL Medical Technologies, ICU Medical Systems, Inc., SCHILLER AG, Bexen Cardio, Progetti S.r.l., Vitatron, Kestra Medical Technologies, Inc., and others.
Show more